Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease

Phase 3

Completed

• Conditions: Crohn's Disease

• Registration Number: NCT00077779
• Lead Sponsor: Abbott

Brief Summary

The purpose of this study is to test whether Adalimumab (at two different doses) can induce and maintain clinical remission in subjects with active Crohn's disease when compared to placebo (a substance containing no medication)

Detailed Description

Not available

Study Timeline

• Study Start: 2003-07
• Study First Submitted: 2004-02-12
• Study First Submitted QC: 2004-02-13
• Study First Posted: 2004-02-16
• Status Verified: 2007-09
• Last Update Submitted: 2007-09-23
• Last Update Posted: 2007-09-26

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 854

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Clinical remission (CDAI<150).	56 weeks

Trial Locations

Locations (43)

Thornton Hospital Reumatology Division; 🇺🇸 La Jolla, California, United States

UCSF San Francisco General Hospital; 🇺🇸 San Francisco, California, United States

Cal-West, Inc.; 🇺🇸 San Francisco, California, United States

Western States Clinical Research; 🇺🇸 Arvada, Colorado, United States

Gastroenterology Associates of Fairfield County; 🇺🇸 Bridgeport, Connecticut, United States

Clinical Research of West Florida, Inc.; 🇺🇸 Clearwater, Florida, United States

V.A. Medical Center; 🇺🇸 Gainsville, Florida, United States

Mark Lamet, MD; 🇺🇸 Hollywood, Florida, United States

Gastroenterology Consultants; 🇺🇸 Ormond Beach, Florida, United States

Northwest Gastroenterology; 🇺🇸 Arlington Heights, Illinois, United States

Scroll for more (33 remaining)